Cardiometabolic innovation is experiencing a renaissance, with new therapies targeting obesity, heart failure, diabetes, CKD, and MASH. Innovators face unique complexity from overlapping co-morbidities, diverse prescriber bases, and multi-indication therapies like GLP-1s and SGLT2s that reset risk baselines. Excellence requires three pillars: deep market insight to map patient journeys and competitive dynamics; aligned value propositions tailored across specialties; and high-quality execution supported by performance transparency. Success stories like Jardiance and Rezdiffra show the importance of early market shaping, targeted engagement, and portfolio-level strategy to capture value and sustain growth.

Join for free to read